![]() |
市场调查报告书
商品编码
1820145
甲状腺功能测试市场报告,按测试类型(TSH 测试、T3 测试、T4 测试等)、适应症(甲状腺功能减退症、甲状腺功能亢进症、甲状腺癌等)、最终用户(医院、诊断实验室等)和地区划分,2025 年至 2033 年Thyroid Function Test Market Report by Test Type (TSH Tests, T3 Tests, T4 Tests, and Others), Indication (Hypothyroidism, Hyperthyroidism, Thyroid Cancer, and Others), End User (Hospitals, Diagnostic Laboratories, and Others), and Region 2025-2033 |
2024年,全球甲状腺功能检测市场规模达17亿美元。展望未来, IMARC Group预计到2033年,该市场规模将达到26.3亿美元,2025-2033年期间的复合年增长率(CAGR)为4.9%。检测设备在精度、速度和可靠性方面的不断进步,个人对家用检测试剂盒的需求不断增长,以及对甲状腺疾病早期发现和治疗的日益重视,都是推动市场成长的一些因素。
诊断技术的进步
自动化检测系统、高通量分析仪和即时检测 (POC) 等创新技术正在提升甲状腺检测的精确度、速度和便利性。这些技术使医疗保健提供者能够更快地提供结果,从而更轻鬆地诊断和治疗甲状腺疾病。此外,人工智慧 (AI) 和机器学习 (ML) 在诊断工具中的整合也提高了甲状腺检测的预测精准度,从而为患者提供更高水准的个人化治疗。此外,家用检测试剂盒的出现简化了患者(尤其是偏远地区或行动不便的患者)监测甲状腺健康状况的过程。检测技术的不断发展推动了医疗保健机构对甲状腺功能检测的需求。 2023 年,西普拉 (Cipla) 推出了 Cippoint,这是一款即时检测设备,可快速检测各种健康问题,例如心臟标记、糖尿病和甲状腺功能。该设备已获得 CE IVD 认证,可在 3 至 15 分钟内得出结果,有助于加快临床决策。 Cippoint 秉持着简化设计的理念,致力于提升城乡医疗环境中的诊断能力。
提高家庭检测试剂盒的可及性
人们正在寻求便利的医疗保健选择,这推动了家用检测试剂盒的需求,因为它们能够追踪甲状腺指标,无需频繁前往实验室。持续的技术进步使家用检测选项更加可靠和精确,使人们能够主动管理自身健康。这一趋势对于那些因地域或时间限製而难以获得传统医疗服务的人尤其具有吸引力。此外,在家中舒适地进行检测的能力正在鼓励更多人接受甲状腺筛检,这为甲状腺功能检测市场带来了良好的前景。 2023年,Healthyr与沃尔玛合作推出了六款家用干血斑检测试剂盒,标誌着它们首次登陆实体店。这些检测涵盖了各种健康指标,例如一般健康、胆固醇、糖化血红蛋白+血糖、甲状腺功能和性传染感染 (STI),可在线上或在超过1200家沃尔玛门市购买。该计画旨在透过提供便捷易得的检测选项,帮助人们管理自身健康。
意识增强和预防保健
随着医疗保健系统转向积极主动的策略,甲状腺疾病和其他慢性疾病的早期发现和治疗日益受到重视。关于甲状腺健康重要性的公众意识宣传活动和教育倡议正在鼓励人们定期进行筛检,尤其是女性和老年人等高风险族群。透过在药局等日常场所推广自我检测,这些措施促进了人们自主掌控自身健康的日益增长的趋势。这种积极主动的方法正在支持甲状腺功能检测市场的成长,因为越来越多的人认识到常规甲状腺筛检对整体健康管理的价值。 2023年,2San和Phoenix Healthcare在药局推出了包括甲状腺检测在内的各种自我诊断检测,以改善个人医疗保健。这些检测在380家Rowlands药局分店和5200家Numark独立药局提供。目标是使自我检测更加普及,使人们能够及早发现健康问题并在需要时寻求帮助。
TSH 测试占据大部分市场份额
TSH 检测因其在甲状腺疾病诊断和监测中的广泛应用而占据市场主导地位。促甲状腺激素 (TSH) 检测是检测甲状腺功能减退症和甲状腺功能亢进症的主要诊断工具,因为它可以测量调节甲状腺功能的荷尔蒙。由于 TSH 检测的准确性、可靠性和成本效益,临床医生更倾向于将其用于甲状腺的初步筛检和常规监测。 TSH 检测的广泛应用和可靠性显着扩大了甲状腺功能检测的整体市场规模,使其成为行业中的主导细分市场。
甲状腺功能减退症占业界最大份额
甲状腺功能减退症是最大的细分市场,这归因于其在世界范围内的高发病率和频繁监测的需求。甲状腺功能减退症是由于甲状腺激素分泌不足引起的,会导致疲劳、体重增加和悲伤等症状。这种疾病在老年人和女性中尤其常见,随着医疗保健意识的提高和常规筛检的普及,确诊病例的数量也不断增加。甲状腺功能减退症需要透过定期甲状腺功能检测持续监测荷尔蒙水平,这推动了此类检测的需求。 2024年,海得拉巴的Niloufer医院启动了一项新生儿筛检项目,旨在识别先天性甲状腺功能减退症和G6PD缺乏症等严重的遗传性疾病。筛检包括在出生后24至48小时内进行的足跟采血检查,通常在5至7天内即可获得结果。该计画是印度一项旨在加强罕见疾病早期诊断和管理的大型活动的组成部分。
医院是主要的细分市场
医院因其庞大的患者数量和先进的诊断设施而占据最大的市场份额。医院通常是甲状腺疾病患者的主要治疗机构,提供一系列服务,例如专业的内分泌科和先进的检测工具。此外,医院通常处理更复杂的情况,例如甲状腺手术和癌症治疗,这些情况需要持续监测甲状腺功能。因此,随着医院内患者对全面诊断和监测解决方案的需求不断增长,甲状腺功能检测市场的价值正在上升。
北美领先市场,占据甲状腺功能检测最大市场份额
该报告还对所有主要区域市场进行了全面分析,包括北美(美国和加拿大);亚太地区(中国、日本、印度、韩国、澳洲、印尼等);欧洲(德国、法国、英国、义大利、西班牙、俄罗斯等);拉丁美洲(巴西、墨西哥等);以及中东和非洲。报告指出,北美是甲状腺功能检测最大的区域市场。
北美占据市场主导地位,因为其拥有先进的医疗设施、高昂的医疗支出以及大量甲状腺问题患者。对预防性医疗保健和定期筛检的高度重视推动了对甲状腺功能测试的需求。此外,桥本甲状腺炎和格雷夫兹病等自体免疫疾病在北美的盛行率相对较高,进一步推动了对持续甲状腺监测的需求。主要市场参与者的存在以及诊断技术的持续研究和创新正在促进市场成长。美国癌症协会预测,2024 年美国将新增约 44,020 例甲状腺癌病例,其中男性 12,500 例,女性 31,520 例。此外,估计约有 2,170 人死于甲状腺癌,其中男性 990 例,女性 1,180 例。
(请注意,这只是关键参与者的部分名单,完整名单在报告中提供。)
The global thyroid function test market size reached USD 1.70 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.63 Billion by 2033, exhibiting a growth rate (CAGR) of 4.9% during 2025-2033. The growing advancements in testing devices for enhancing precision, speed, and reliability, rising demand for at-home testing kits among individuals, and increasing emphasis on early detection and treatment of thyroid disorders are some of the factors impelling the market growth.
Advances in Diagnostic Technologies
Innovations, like automated testing systems, high-throughput analyzers, and POC testing devices, are enhancing the precision, speed, and ease of thyroid testing. These technologies allow healthcare providers to provide faster outcomes, making it easier to diagnose and treat thyroid disorders. Additionally, the integration of artificial intelligence (AI) and machine learning (ML) in diagnostic tools is improving the predictive precision of thyroid tests, leading to a higher level of tailored patient treatment. Furthermore, the creation of testing kits for use at home are simplifying the process of monitoring thyroid health for patients, particularly those in remote locations or individuals experiencing mobility challenges. The growing advancements in testing technology are driving the thyroid function test demand in healthcare settings. In 2023, Cipla revealed Cippoint, a device for POC testing that offered rapid testing for various health issues, such as cardiac markers, diabetes, and thyroid function. CE IVD approved, the device produced outcomes within a 3 to 15 minutes timeframe, aiding in faster clinical decision-making. Created for simplicity, Cippoint strived to improve diagnostic abilities in urban and rural healthcare environments.
Increasing Accessibility of At-Home Testing Kits
Individuals are looking for convenient healthcare options, which is driving the demand for at-home testing kits because of their ability to track thyroid without the need for frequent laboratory visits. The continuous technological progress is making home testing options more dependable and precise, empowering individuals to manage their health actively. This trend is particularly appealing to those who may have difficulty accessing traditional healthcare services because of geographical or time constraints. Furthermore, the ability to perform tests comfortably at home is encouraging more people to undergo thyroid screening, offering a favorable thyroid function test market outlook. In 2023, Healthyr introduced six dried blood spot test kits for home use in partnership with Walmart, marking their debut in brick-and-mortar stores. The available tests cover various health aspects like general health, cholesterol, HbA1c + glucose, thyroid function, and sexually transmitted infections (STIs), and can be purchased online or at over 1,200 Walmart stores. This project seeks to enable people to manage their health by offering convenient and easily accessible testing options.
Growing Awareness and Preventive Healthcare
With healthcare systems moving towards proactive strategies, there is an emphasis on early detection and treatment of thyroid disorders and other chronic conditions. Public awareness campaigns and educational initiatives about the significance of thyroid health are encouraging individuals to seek regular screenings, particularly those at higher risk, such as women and older adults. By promoting self-testing in everyday settings like pharmacies, these efforts contribute to the growing trend of empowering people to take control of their health. This proactive approach is supporting the thyroid function test market growth, as more individuals recognize the value of routine thyroid screening for overall health management. In 2023, 2San and Phoenix Healthcare introduced a variety of self-diagnostic tests in pharmacies, including a thyroid test, to improve individual health care. These tests were made available at 380 Rowlands Pharmacy branches and 5,200 Numark independent pharmacies. The goal was to make self-testing more common, enabling people to detect health problems early and seek help as needed.
TSH tests account for the majority of the market share
TSH tests dominate the market because of their widespread use in diagnosing and monitoring thyroid disorders. Thyroid stimulating hormone (TSH) tests are the primary diagnostic tool for detecting both hypothyroidism and hyperthyroidism, as they measure the hormone that regulates the thyroid gland's function. Clinicians prefer using TSH tests for initial thyroid screenings and routine monitoring due to their accuracy, reliability, and cost-effectiveness. The extensive usage and reliability of TSH tests notably contribute to the overall thyroid function test market size, making it a dominant segment in the industry.
Hypothyroidism holds the largest share of the industry
Hypothyroidism represents the largest segment attributed to its high prevalence worldwide and the requirement for frequent monitoring. Hypothyroidism is the result of inadequate hormone production by the thyroid gland, causing symptoms like tiredness, increased weight, and feelings of sadness. The condition is particularly common in older adults and women, with a growing number of cases being diagnosed due to increased healthcare awareness and routine screenings. Hypothyroidism requires continuous monitoring of hormone levels through regular thyroid function testing, which is driving the demand for these tests. In 2024, Niloufer Hospital in Hyderabad initiated a newborn screening program to identify serious genetic disorders like congenital hypothyroidism and G6PD deficiency. The screening includes a heel prick test done between 24 and 48 hours after birth, with results typically ready in five to seven days. This project is a component of a larger campaign to enhance the early diagnosis and management of rare diseases in India.
Hospitals represent the leading market segment
Hospitals hold the biggest market share because of the large patient volume and the presence of advanced diagnostic facilities. Hospitals are commonly the main source of treatment for individuals with thyroid issues, providing a range of services such as specialized endocrinology units and advanced testing tools. Furthermore, hospitals often deal with more intricate situations like thyroid surgeries and cancer treatments that necessitate continuous monitoring of thyroid function. As a result, the thyroid function test market value is rising, driven by the growing demand for comprehensive diagnostic and monitoring solutions among patients within hospital settings.
North America leads the market, accounting for the largest thyroid function test market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for thyroid function test.
North America dominates the market because of advanced healthcare facilities, high healthcare expenditure, and a large population with thyroid issues. The strong focus on preventive healthcare and regular screenings is driving the demand for thyroid function tests. Additionally, the prevalence of autoimmune diseases, such as Hashimoto's thyroiditis and Graves' disease, is relatively high in North America, further driving the need for consistent thyroid monitoring. The presence of key market players and continuous research and innovation in diagnostic technologies is bolstering the market growth. The American Cancer Society predicts around 44,020 new thyroid cancer cases in the United States in 2024, including 12,500 in men and 31,520 in women. Moreover, the estimates suggest about 2,170 fatalities due to thyroid cancer, with 990 in males and 1,180 in females.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)